Information Provided By: 
Fly News Breaks for January 17, 2017
AGIO
Jan 17, 2017 | 07:33 EDT
As previously reported, Oppenheimer analyst Leah Rush Cann upgraded Agios Pharmaceuticals to Outperform from Perform, with a $75 price target, after the company announced and detailed an FDA filing strategy for its wholly-owned compound, AG-120. The analyst anticipates Agios will launch its first drug, AG-221, in partnership with Celgene Corporation, in 2017 and its second drug, AG-120, in 2018, two years sooner than he previously estimated.
News For AGIO From the Last 2 Days
There are no results for your query AGIO
